Figure 9.
Effects of MMI-0100 treatment on LPS-induced inflammatory response and the expression of pMK2 in BV-2 cells. (A) MMI-0100 reduces LPS (1 μg/ml)-induced release of pro-inflammatory mediators such as IL-6, IL-1β, TNF-α, COX-2, and iNOS level in BV-2 cells. (B) The upper panel is a representative immunoblot of pMK2, tMK2, and GAPDH detected by Western blotting; the lower panel is quantification of MK2 expressed as the ratio of pMK2/tMK2. **p < 0.01 compared with vehicle group vs LPS group. #p < 0.05 and ##p < 0.01 compared with the LPS group vs. LPS + MMI-0100 (10−5, 10−6, 10−7, and 10−8 M) at different doses. Values were expressed as mean ± SEM.